Crofelemer for the treatment of chronic diarrhea in patients living with HIV/AIDS

HIV/AIDS - Research and Palliative Care

Volumn 5, Issue , 2013, Pages 153-162

  Patel, Twisha S ^a   Crutchley, Rustin D ^a   Tucker, Anne M ^a   Cottreau, Jessica ^a   Garey, Kevin W ^a  

^a UNIVERSITY OF HOUSTON   (United States)

Author keywords

Antiretrovirals; Crofelemer; HIV; Secretory diarrhea

Indexed keywords

ATAZANAVIR PLUS RITONAVIR; ATROPINE PLUS DIPHENOXYLATE; CROFELEMER; DARUNAVIR PLUS RITONAVIR; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; FOSAMPRENAVIR PLUS RITONAVIR; INTEGRASE INHIBITOR; LAMIVUDINE; LOPERAMIDE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PLACEBO; PROTEINASE INHIBITOR; RITONAVIR; RITONAVIR PLUS SAQUINAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ABDOMINAL PAIN; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIDIARRHEAL ACTIVITY; BRONCHITIS; CHRONIC DIARRHEA; CONSTIPATION; COUGHING; DIARRHEA; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DYSPEPSIA; ENTEROPATHY; FLATULENCE; HEMORRHOID; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTIOUS DIARRHEA; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; TRAVELLER DIARRHEA; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

EID: 84880424446     PISSN: None     EISSN: 11791373     Source Type: Journal    
DOI: 10.2147/HIV.S30948     Document Type: Review

References (40)

1. Zingmond DS, Kilbourne AM, Justice AC, et al. Differences in symptom expression in older HIV-positive patients: the Veterans Aging Cohort 3 Site Study and HIV Cost and Service Utilization Study experience. J Acquir Immune Defic Syndr. 2003;33 Suppl 2:S84-S92.
2. MacArthur RD, DuPont HL. Etiology and pharmacologic management of noninfectious diarrhea in HIV-infected individuals in the highly active antiretroviral therapy era. Clin Infect Dis. 2012;55(6):860-867.
3. Lorenz KA, Shapiro MF, Asch SM, Bozzette SA, Hays RD. Associations of symptoms and health-related quality of life: findings from a national study of persons with HIV infection. Ann Intern Med. 2001;134(9 Pt 2): 854-860.
4. Siddiqui U, Bini EJ, Chandarana K, et al. Prevalence and impact of diarrhea on health-related quality of life in HIV-infected patients in the era of highly active antiretroviral therapy. J Clin Gastroenterol. 2007;41(5):484-490.
5. Hill A, Balkin A. Risk factors for gastrointestinal adverse events in HIV treated and untreated patients. AIDS Rev. 2009;11(1):30-38.
6. Siegel K, Schrimshaw EW, Brown-Bradley CJ, Lekas HM. Sources of emotional distress associated with diarrhea among late middle-age and older HIV-infected adults. J Pain Symptom Manage. 2010;40(3): 353-369.
7. Tradtrantip L, Namkung W, Verkman AS. Crofelemer, an antisecretory antidiarrheal proanthocyanidin oligomer extracted from Croton lechleri, targets two distinct intestinal chloride channels. Mol Pharmacol. 2010;77(1):69-78.
8. Zhang W, Fujii N, Naren AP. Recent advances and new perspectives in targeting CFTR for therapy of cystic fibrosis and enterotoxin-induced secretory diarrheas. Future Med Chem. 2012;4(3):329-345.
9. Thiagarajah JR, Verkman AS. CFTR inhibitors for treating diarrheal disease. Clin Pharmacol Ther. 2012;92(3):287-290.
10. Barrett KE, Keely SJ. Chloride secretion by the intestinal epithelium: molecular basis and regulatory aspects. Annu Rev Physiol. 2000;62: 535-572.
11. Sherman DS, Fish DN. Management of protease inhibitor-associated diarrhea. Clin Infect Dis. 2000;30(6):908-914.
12. Berni Canani R, Secondo A, Passariello A, et al. Zinc inhibits calciummediated and nitric oxide-mediated ion secretion in human enterocytes. Eur J Pharmacol. 2010;626(2-3):266-270.
13. Primi MP, Bueno L, Baumer P, Berard H, Lecomte JM. Racecadotril demonstrates intestinal antisecretory activity in vivo. Aliment Pharmacol Ther. 1999; 13 Suppl 6:3-7.
14. Holodniy M, Koch J, Mistal M, et al. A double blind, randomized, placebo-controlled phase II study to assess the safety and efficacy of orally administered SP-303 for the symptomatic treatment of diarrhea in patients with AIDS. Am J Gastroenterol. 1999;94(11):3267-3273.
15. DiCesare D, DuPont HL, Mathewson JJ, et al. A double blind, randomized, placebo-controlled study of SP-303 (Provir) in the symptomatic treatment of acute diarrhea among travelers to Jamaica and Mexico. Am J Gastroenterol. 2002;97(10):2585-2588.
16. Mangel AW, Chaturvedi P. Evaluation of crofelemer in the treatment of diarrhea-predominant irritable bowel syndrome patients. Digestion. 2008;78(4):180-186.
17. Bardhan P, Sharma A, Bolmall C, et al. Safety and efficacy of a novel anti-secretory anti-diarrheal agent crofelemer (NP-303), in the treatment of adult acute infectious diarrhea and cholera, with or without the use of antibiotics. Proceedings of the US-Japan CMSP: 13th International Conference on Emerging Infectious Diseases (EID) in the Pacific Rim-Focused on Enteric Diseases; April 6-9, 2009; Kolkata, India.
18. Kartalija M, Sande MA. Diarrhea and AIDS in the era of highly active antiretroviral therapy. Clin Infect Dis. 1999;28(4):701-705.quiz 706-707.
19. Brenchley JM, Douek DC. HIV infection and the gastrointestinal immune system. Mucosal Immunol. 2008;1(1):23-30.
20. Malan N, Su J, Mancini M, et al; for CASTLE Study Team. Gastrointestinal tolerability and quality of life in antiretroviral-naïve HIV-1-infected patients: data from the CASTLE study. AIDS Care. 2010;22(6):677-686.
21. Johnson M, Grinsztejn B, Rodriguez C, et al. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS. 2005;19(7):685-694.
22. Johnson M, Grinsztejn B, Rodriguez C, et al. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS. 2006;20(5):711-718.
23. Molina JM, Andrade-Villanueva J, Echevarria J, et al; for CASTLE Study Team. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet. 2008;372(9639):646-655.
24. Molina JM, Andrade-Villanueva J, Echevarria J, et al; for CASTLE Study Team. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. J Acquir Immune Defic Syndr. 2010;53(3):323-332.
25. Bánhegyi D, Katlama C, da Cunha CA, et al. Week 96 efficacy, virology and safety of darunavir/r versus lopinavir/r in treatment-experienced patients in TITAN. Curr HIV Res. 2012;10(2):171-181.
26. Madruga JV, Berger D, McMurchie M, et al; for TITAN Study Group. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. Lancet. 2007;370(9581):49-58.
27. Mills AM, Nelson M, Jayaweera D, et al. Once-daily darunavir/ritonavir vs lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. AIDS. 2009;23(13):1679-1688.
28. Ortiz R, Dejesus E, Khanlou H, et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS. 2008;22(12):1389-1397.
29. Walmsley S, Avihingsanon A, Slim J, et al. Gemini: a noninferiority study of saquinavir/ritonavir versus lopinavir/ritonavir as initial HIV-1 therapy in adults. J Acquir Immune Defic Syndr. 2009;50(4): 367-374.
30. Eron J Jr, Yeni P, Gathe J Jr, et al; for KLEAN Study Team. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet. 2006;368(9534):476-482.
31. Pulido F, Estrada V, Baril JG, et al. Long-term efficacy and safety of fosamprenavir plus ritonavir versus lopinavir/ritonavir in combination with abacavir/lamivudine over 144 weeks. HIV Clin Trials. 2009;10(2): 76-87.
32. Hicks CB, DeJesus E, Sloan LM, et al; for COL100758 Study Team. Comparison of once-daily fosamprenavir boosted with either 100 or 200 mg of ritonavir, in combination with abacavir/lamivudine: 96-week results from COL100758. AIDS Res Hum Retroviruses. 2009;25(4): 395-403.
33. Braga Neto MB, Aguiar CV, Maciel JG, et al. Evaluation of HIV protease and nucleoside reverse transcriptase inhibitors on proliferation, necrosis, apoptosis in intestinal epithelial cells and electrolyte and water transport and epithelial barrier function in mice. BMC Gastroenterol. 2010;10:90.
34. Rufo PA, Lin PW, Andrade A, et al. Diarrhea-associated HIV-1 APIs potentiate muscarinic activation of Cl-secretion by T84 cells via prolongation of cytosolic Ca2+ signaling. Am J Physiol Cell Physiol. 2004;286(5):C998-C1008.
35. MacArthur R, Hawkins T, Brown S, LaMarca A, Chaturvedi P, Ernst J. ADVENT Trial: crofelemer for the treatment of secretory diarrhea in HIV+ individuals. Proceedings of the 19th Conference on Retroviruses and Opportunistic Infections; March 5-8, 2012; Seattle, WA.
36. Fulyzaq® (crofelemer) [prescribing Information]. Raleigh, NC: Salix Pharmaceuticals, Inc; 2013. Available from: http://www.fulyzaq.com/. Accessed April 1, 2013.
37. Fischer H, Machen TE, Widdicombe JH, et al. A novel extract SB-300 from the stem bark latex of Croton lechleri inhibits CFTR-mediated chloride secretion in human colonic epithelial cells. J Ethnopharmacol. 2004;93(2/3):351-357.
38. Ubillas R, Jolad S, Bruening RC, et al. SP-303, an antiviral oligomeric proanthocyanidin from the latex of Croton lechleri (Sangre de Drago). Phytomedicine. 1994;1(2):77-106.
39. Gabriel SE, Davenport SE, Steagall RJ, Vimal V, Carlson T, Rozhon EJ. A novel plant-derived inhibitor of cAMP-mediated fluid and chloride secretion. Am J Physiol. 1999;276(1 Pt 1):G58-G63.
40. + individuals: results from double-blind and open-label studies. Proceedings of the 20th Conference on Retroviruses and Opportunistic Infections; March 3-6, 2013; Atlanta, GA.